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Abstract
Background: Umbilical cord blood (UCB) is enriched with transplantable CD34+ cells. In addition
to CD34-expressing haematopoietic stem cells (HSC), human UCB contains a rare population of
CD34-lineage- cells endowed with the ability to differentiate along the T/NK pathway in response
to interleukin (IL)-15 and a stromal cell support. IL-21 is a crucial regulator of NK cell function,
whose influence on IL-15-induced differentiation of CD34-lineage- cells has not been investigated
previously. The present study was designed and conducted to address whether IL-21 might replace
the stromal cell requirements and foster the IL-15-induced NK differentiation of human UCB
CD34-lineage- cells.
Results: CD34-lineage- cells were maintained in liquid culture with Flt3-L and SCF, with the
addition of IL-15 and IL-21, either alone or in combination. Cultures were established in the
absence of feeder cells or serum supplementation. Cytokine-treated cells were used to evaluate
cell surface phenotype, expression of molecular determinants of lymphoid/NK cell differentiation,
secretion of IFN-γ, GM-CSF, TNF-α and CCL3/MIP-1α, and cytolytic activity against NK-sensitive
tumour cell targets. CD34-lineage- cells proliferated vigorously in response to IL-15 and IL-21 but
not to IL-21 alone, and up-regulated phosphorylated Stat1 and Stat3 proteins. CD34-lineage- cells
expanded by IL-21 in combination with IL-15 acquired lymphoid morphology and killer-cell
immunoglobulin-like receptor (KIR)-CD56+CD16-/+ phenotype, consistent with pseudo-mature
NK cells. IL-21/IL-15-differentiated cells expressed high levels of mRNA for Bcl-2, GATA-3 and Id2,
a master switch required for NK-cell development, and harboured un-rearranged TCRγ genes.
From a functional standpoint, IL-21/IL-15-treated cells secreted copious amounts of IFN-γ, GM-CSF
and CCL3/MIP-1α, and expressed cell surface CD107a upon contact with NK-sensitive tumour
targets, a measure of exocytosis of NK secretory granules.
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BMC Immunology 2009, 10:46 http://www.biomedcentral.com/1471-2172/10/46Conclusion: This study underpins a novel role for IL-21 in the differentiation of pseudo-mature
lytic NK cells in a synergistic context with IL-15, and identifies a potential strategy to expand
functional NK cells for immunotherapy.
Background
Umbilical cord blood (UCB) is increasingly used as an
alternative source of transplantable CD34+ haematopoi-
etic stem cells (HSC) for neoplastic and non-neoplastic
diseases [1]. The function of CD34 antigen on human
HSC is poorly understood. It has been shown that small
interfering RNA-mediated gene silencing of CD34 on
human HSC from UCB favours granulocytic and meg-
akaryocytic development at the expense of erythroid com-
mitment, thus shedding light into the potential functional
role of this molecule during haematopoietic differentia-
tion [2]. In recent years, HSC with a CD34- phenotype
have been identified in human UCB, unravelling a hith-
erto unrecognized complexity within the haematopoietic
hierarchy [3,4]. Previously, we characterized a rare sub-
population of human UCB CD34-CD133-CD7-lineage-
cells capable of differentiating both into CD34+CD133+
HSC in response to stem cell factor (SCF), and into NK/
lymphoid progenitors if supported by interleukin (IL)-15
and stromal cells engineered to release human granulo-
cyte colony-stimulating factor (G-CSF) and IL-3 [5]. In
line with this, UCB-derived mesenchymal stem cells have
been used to support NK cell expansion induced by the
combination of IL-2, IL-3, IL-15 and Flt3-L [6]. Similarly,
Wharton's jelly cells may serve as feeder cells to expand
UCB-derived CD34+ HSC in a potentially clinically appli-
cable culture system [7]. It should be pointed out that
mesenchymal stem cells may activate allogeneic T cells
during in vitro HSC expansion [8], suggesting need for
feeder cell-free culture systems that may support HSC
expansion in the absence of untoward effects on other cell
types.
IL-21 is a four-helix bundle cytokine released by activated
CD4+ T cells and by NKT cells [9]. IL-21 signals through a
heterodimeric receptor comprising the IL-21 receptor and
the common γc of the IL-2 receptor family. IL-21 affects
the differentiation and proliferation of NK cells together
with IL-2 and IL-15, and is involved in the differentiation
of T-helper 17 (Th17) cells, a recently identified subset of
CD4+ T cells that produce IL-17A, IL-17F and IL-22 and
promote inflammatory and autoimmune conditions [10].
In addition, IL-21 suppresses the differentiation of FoxP3-
expressing regulatory T cells, leading to enhanced cyto-
toxic T lymphocyte (CTL) expansion and activity [11].
Finally, IL-21 is a key regulator of antibody responses
against foreign antigens [12], suggesting that IL-21 may be
a master orchestrator of the T-cell-dependent adaptive
immune response.
In mice, IL-21 acts in concert with IL-15 to boost the pro-
liferation of both memory and naïve CD8+ T cells and to
foster the in vitro release of IFN-γ [13]. Interestingly, IL-21
selectively enhances the effector functions of IL-15-acti-
vated murine NK cells, further underpinning the impor-
tance of functional interactions between the two
cytokines, and mediates potent in vivo anti-tumour
responses [14]. When provided to serum-replenished cul-
tures of UCB CD34+lineage- cells, IL-21 in combination
with IL-15, IL-7, Flt3-L and SCF reportedly induces an
accelerated NK cell maturation [15]. Furthermore, IL-21
cooperates with hydrocortisone, IL-15 and Flt3-L in sup-
porting the expansion of NK cells from UCB CD34+ cells
[16]. However, the contribution of IL-21, if any, to the NK
cell differentiation of CD34-lineage- cells has not been
investigated. It is also unknown whether CD34-lineage-
cells stimulated with IL-21 may give rise to a qualitatively
different NK population when compared to CD34+ HSC.
The present study aimed to address whether IL-21 might
replace the stromal cell requirements and foster the IL-15-
induced NK differentiation of human UCB CD34-lineage-
cells.
Results
Isolation and phenotypic characterisation of UCB CD34-
lineage- cells
Freshly isolated CD34-lineage- cells stained negatively for
stem cell-associated (CD34, CD133) and NK/lymphoid
surface antigens (CD7, CD56, CD16, CD3, TCRαβ; data
not shown), and comprised 0.22% on average of UCB
mononuclear cells (samples analyzed = 11). The afore-
mentioned frequency of CD34- cells is in good agreement
with that reported by others [3]. CD34-lineage- cells
expressed low levels of IL-21 receptor protein (Figure 1A).
The expression of IL-21 receptor in control samples, e.g.,
UCB CD34+ HSC and human peripheral blood B cells, is
shown in Figure 1B and Figure 1C, respectively. Following
the observation that Stat1/Stat3 deficient CD8+ T cells
manifest decreased responsiveness to IL-21 [17], we
attempted to determine whether IL-21 induced Stat pro-
tein phosphorylation in CD34-lineage- cells. When freshly
isolated CD34-lineage- cells were stimulated with 20 ng/
ml IL-21 for 4 hours, both phosphorylated Stat1 and
phosphorylated Stat3 were induced, whereas phosphor-
ylated Stat5 levels remained unaffected (Figure 1D).
CD34-lineage- cells were next maintained with SCF and
Flt3-L for up to 4 weeks, and IL-15 or IL-21 or the combi-Page 2 of 15
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BMC Immunology 2009, 10:46 http://www.biomedcentral.com/1471-2172/10/46nation of both cytokines was supplemented to SCF+Flt3-
L-containing cultures as indicated in the Figure legends.
Either IL-15 alone or, even more dramatically, the combi-
nation of IL-15 and IL-21 activated the proliferation of
CD34-lineage- cells (Figure 2A). After culturing with Flt3-
L and SCF supplemented with the combination of IL-15
and IL-21, CD34-lineage- cells were expanded by 42.5-fold
on average (Figure 2B), in contrast with the effects of Flt3-
L and SCF either alone or supplemented with IL-15 or IL-
21 individually. Control cultures were comprised of UCB
Expression of IL-21 receptor on CD34-lineage- cells and Stat protein activation by IL-21Figure 1
Expression of IL-21 receptor on CD34-lineage- cells and Stat protein activation by IL-21. Panel A: Freshly isolated 
CD34-lineage- cells were incubated with APC-conjugated anti-IL-21 receptor mAb, followed by flow cytometry analysis. Iso-
type-matched, irrelevant mAb were used to control for background staining (cyan histogram). One representative experiment 
out of 4 with similar results is shown. Panel B: CD34+ cells were separated from UCB samples using the MACS® system, as 
detailed in Material and Methods. Cells were labelled with anti-IL-21 receptor mAb prior to flow cytometry analysis. Isotype-
matched, irrelevant mAb were used to control for background staining (cyan histogram). One representative experiment out 
of 4 with similar results is shown. Panel C: Mononuclear cells from the peripheral blood of healthy blood donors were 
labelled with anti-IL-21 receptor mAb prior to flow cytometry analysis. Markers were set according to the proper isotypic con-
trol. One representative experiment out of 4 with similar results is shown. Panel D: Stat protein phosphorylation was meas-
ured after provision of either 50 ng/ml IL-15 (white columns) or 50 ng/ml IL-15 + 20 ng/ml IL-21 (red columns) to freshly 
isolated CD34-lineage- cells. Bars depict the mean and standard deviation recorded in 4 independent experiments performed in 
triplicate. The blue bars depict the level of phosphorylated Stat1 (Tyr701), Stat3 (Tyr705) and Stat5 (Tyr694) in freshly isolated 
peripheral blood mononuclear cells, used as control.
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BMC Immunology 2009, 10:46 http://www.biomedcentral.com/1471-2172/10/46CD34+ cells exposed to the same cytokine combinations
as the CD34-lineage- cells. CD34+ cells were incapable of
responding to IL-21 alone (data not shown), in accord-
ance with previous reports demonstrating lack of IL-21
receptor expression on freshly isolated CD34+ cells [16].
As illustrated in Figure 2c, CD34+ cells expanded vigor-
ously in response to Flt3-L and SCF, either alone or sup-
plemented with IL-15. However, proliferation was
significantly increased in CD34+ cell cultures containing
both IL-15 and IL-21, indicating synergistic effects of the
two γc signalling cytokines. Interestingly, CD34+ cell
expansion promoted by Flt3-L and SCF was constrained
Expansion of CD34-lineage- cells in response to IL-15 plus IL-21Figure 2
Expansion of CD34-lineage- cells in response to IL-15 plus IL-21. CD34-lineage- cells were maintained in liquid cultures 
with Flt3-L and SCF, in the presence of either IL-15, or IL-21 or the combination of both cytokines for up to 4 weeks. In order 
to monitor cell expansion in response to cytokine stimulation, cells were harvested weekly and counted. CD34+ cells isolated 
from the same UCB samples were used in control experiments. Panel A: Cultures were established with CD34-lineage- cells. 
The number of viable cells was counted using trypan blue exclusion. The bars depict mean and standard deviation recorded in 
11 independent experiments performed with 11 different UCB samples. Panel B: Fold expansion of the CD34-lineage- cells 
after 4 weeks of culture with either of the cytokine combinations. The bars depict mean and standard deviation recorded in 11 
independent experiments performed with 11 different UCB samples. Panel C: Fold expansion of UCB CD34+ cells after 4 
weeks of culture with either of the cytokine combinations. The bars depict mean and standard deviation recorded in 5 inde-
pendent experiments performed with 5 different UCB samples. Panel D: After 4 weeks of culture with IL-21 and IL-15, CD34-
lineage- cells were harvested, stained with May-Grünwald-Giemsa and visualized under an AX70 optical microscope (Olympus, 
Tokyo, Japan) equipped with 100×/1.25 NA objective lens. Image acquisition was performed with an Optronics digital camera 
(Olympus) and ImagePro Plus software (Media Cybernetics, Silver Spring, MD).
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BMC Immunology 2009, 10:46 http://www.biomedcentral.com/1471-2172/10/46by the addition of IL-21 (Figure 2C). Not unexpectedly,
CD34-lineage- cells nurtured with IL-15 either alone or in
combination with IL-21 acquired a peculiar lymphoid
morphology with eccentric nuclei and heavy cytoplasmic
granules (Figure 2D).
We investigated the expression of an array of potentially
informative activation/differentiation antigens on
cytokine-modulated CD34-lineage- cells. The results of
immunophenotypic studies are summarised in Table 1. As
depicted in Figure 3, neither CD158a nor CD158b anti-
gens could be detected on IL-15-differentiated CD34-line-
age- cells. Consistent with the surface phenotype assigned
to pseudo-mature NK cells [18], a minute percentage (<
3%) of IL-15+IL-21-differentiated cells expressed CD158a
and CD158b, indicating that killer-cell immunoglobulin-
like receptors (KIR) were not induced by either cytokine
on CD34-lineage- cells. Whereas CD56 was highly
expressed by CD34-lineage- cells cultured with either IL-15
alone or the combination of IL-15 and IL-21, a minor sub-
set of CD56+CD16+ cells could be consistently detected
both in cultures maintained with IL-15 alone and in those
nurtured with IL-15+IL-21. NKp46, a NK triggering recep-
tor [19], was found on significantly higher percentages of
cells cultured with IL-15 and IL-21 compared with those
maintained with IL-15 alone. Conversely, the CD94-
Phenotypic features of cytokine-differentiated CD34-lineage- cellsFigure 3
Phenotypic features of cytokine-differentiated CD34-lineage- cells. After 4 weeks of culture with either IL-15 or the 
combination of IL-15 and IL-21, CD34-lineage- cells were harvested, stained with a panel of mAb directed against informative 
differentiation/maturation antigens and used for flow cytometry analysis. Fluorochrome-conjugated, isotype-matched mAb 
from the same manufacturers were used to measure background fluorescence. Mononuclear cells (MNC) from UCB and 
peripheral blood (PB) samples as well as NK cells matured in vitro with Flt3-L, SCF, IL-15 and IL-21 from UCB CD34+ cells 
(CD34+-NK15+21) were used as control for antigen expression. The percentage of cells staining positively for each given antigen 
is indicated in the dot plots. One representative experiment out of 8 with similar results is shown.
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BMC Immunology 2009, 10:46 http://www.biomedcentral.com/1471-2172/10/46NKG2A inhibitory receptor complex was expressed by
comparable percentages of IL-15-differentiated and IL-21/
IL-15-differentiated CD34-lineage- cells (Figure 3).
Finally, NKG2D, a powerful activating receptor involved
in the regulation of immune responses during infection,
cancer and autoimmunity [20], was preferentially
detected on CD34-lineage- cells cultured with IL-15 and
IL-21 (Figure 3). The immunophenotypic characteristics
of NK cells differentiated in vitro from UCB CD34+ cells
and those of NK cells from UCB and peripheral blood are
depicted in Figure 3. When compared with CD34-derived
NK cells and with pre-formed NK cells, CD34-lineage- cells
emerging from IL-15+IL-21-containing cultures expressed
very low levels of CD16 and KIR, but high levels of CD56,
NKG2D and IL-21 receptor. Because NKG2D expression
may be negatively regulated by TGF-β [21], we added
exogenous TGF-β at 5 ng/ml to CD34-lineage- cells con-
comitant with their exposure to IL-15 and IL-21. Under
these conditions, less than 5% of developing NK cells
stained positively for NKG2D (data not shown), suggest-
ing that NKG2D expression induced by IL-15 and IL-21
was sensitive to cytokine regulation. Insufficient numbers
of cells for detailed phenotypic analyses were recovered
from cultures performed with Flt3-L and SCF either alone
or supplemented with IL-21, thus precluding a thorough
evaluation of the expression pattern of NK cell-associated
antigens on those cell populations (data not shown).
Molecular profile of IL-21-differentiated CD34-lineage- 
cells
We next aimed to get insights into the expression levels of
mRNA encoding for NK-associated transcription factors.
The provision of IL-15 and IL-21 to CD34-lineage- cells
was associated with up-regulated mRNA signals for Bcl-2,
GATA-3 and, perhaps more importantly, Id2, a master
switch implicated in the commitment of bi-potent foetal
thymus T/NK progenitors to NK cells (Figure 4A) [22].
Notably, Bcl-2 induction by IL-21 has also been demon-
strated in T cells, leading to their enhanced survival
through the activation of the PI-3K signalling pathway
[23].
Because T-cell precursors residing in the foetal liver,
spleen and blood possess NK lineage potential, we aimed
to determine whether NK differentiation in response to
IL-15 and IL-21 occurred in association with TCR rear-
rangement. Previously, we have detected rearranged TCRγ
genes in CD34-lineage- UCB cells cultured with IL-15 and
a stromal cell support [5]. The TCRγ chain gene has 2 con-
stant (C), 5 joining (J) and 14 variable (V) region seg-
ments. Most variable region (Vγ) rearrangements occur
within the Vγ1–8 subgroup and most joining region (Jγ)
rearrangements involve the Jγ1/2 segment [24]. In order
to increase TCRγ rearrangement detection rate, we used
multiple primer sets specific for C and J regions of the
TCRγ chain, as detailed in Materials and Methods. As
shown in Figure 4B, CD34-lineage- cells cultured with IL-
15 and IL-21 harboured un-rearranged TCRγ genes, simi-
lar to freshly isolated CD34-lineage- cells and to cells
maintained with SCF and Flt3-L either alone or supple-
mented with IL-21. This observation suggests that NK
commitment under the experimental conditions here
established occurs through a pathway that does not
include TCR rearrangement.
Cytokine/chemokine secretion by IL-21-differentiated NK 
cells
We next determined the ability of IL-15+IL-21-differenti-
ated cells to release IFN-γ, GM-CSF, TNF-α and CCL3/
MIP-1α in culture supernatants. IFN-γ was undetectable
(< 8 pg/ml) after cell culture in the presence of SCF and
Flt3-L supplemented with either IL-15 or IL-21 alone. In
sharp contrast, exposure to IL-15 and IL-21 induced a
highly significant release of IFN-γ in 4-week old cultures,
corresponding to a mean of 1210 ± 245 pg/ml in 10 inde-
pendent experiments. IFN-γ release by CD34+ HSC
matured with IL-15 and IL-21 was superimposable (data
not shown). GM-CSF was undetectable in Flt3-L+SCF-dif-
Table 1: Surface phenotype of cytokine-differentiated and freshly isolated NK cells.
Cell surface antigen UCB MNC PB MNC CD34+-derived NK cells
(15+21)
CD34-lineage- derived
NK cells
(IL-15)
CD34-lineage- derived
NK cells
(15+21)
CD56+ 23 ± 5 35.4 ± 9 22.9 ± 5 94 ± 2 92 ± 2
CD56+16+ 14.5 ± 7 29.5 ± 5 6.5 ± 2 4 ± 1 0.6 ± 0.2
CD56+94+ 20.9 ± 4 26.7 ± 7 17.6 ± 4 47.5 ± 8 52 ± 5
CD56+NKp46+ 22.3 ± 5 28.6 ± 4 21.1 ± 4 65.5 ± 8 91.5 ± 1
CD56+NKG2D+ 15.4 ± 2 31.4 ± 9 5.0 ± 0.8 16.5 ± 4 68.5 ± 5
CD56+158a+ 4.6 ± 1 4.5 ± 1.5 0.6 ± 0.5 0.01 ± 0.01 0.5 ± 0.2
CD56+158b+ 5.9 ± 1 11.5 ± 6 1.2 ± 1 0.1 ± 0.1 1.8 ± 0.5
CD56+161+ 23.3 ± 6 32.2 ± 7 1.5 ± 0.5 8.3 ± 2 2.1 ± 0.5
CD56+244+ 16.9 ± 6 30.8 ± 4 19.8 ± 5 89.6 ± 5 81.7 ± 2
IL-21R+ 3.6 ± 0.9 2.2 ± 1 12.9 ± 6 94.2 ± 2 76.5 ± 3Page 6 of 15
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BMC Immunology 2009, 10:46 http://www.biomedcentral.com/1471-2172/10/46ferentiated cultures but was released at high levels from
week +3 onward in CD34-lineage- cultures nurtured with
IL-15 alone or with IL-15+IL-21. Conversely, TNF-α was
preferentially detected in the supernatants of IL-15-differ-
entiated CD34-lineage- cells compared with cells main-
tained with IL-15 and IL-21. GM-CSF and TNF-α release
by CD34+ HSC followed a similar pattern, although the
magnitude of cytokine release was significantly lower
when compared with CD34-lineage- cultures. Finally,
measurable CCL3/MIP-1α secretion occurred under any
culture condition that we established. However, CCL3/
MIP-1α release in response to Flt3-L and SCF was further
enhanced by IL-15 alone and, to a greater extent, by IL-15
and IL-21 in combination (Figure 5). Notably, NK cells
differentiated with IL-15 from CD34+ HSC released the
highest levels of CCL3/MIP-1α. Collectively, these experi-
Molecular profile of CD34-lineage- cells differentiated with IL-15 plus IL-21Figure 4
Molecular profile of CD34-lineage- cells differentiated with IL-15 plus IL-21. Panel A: Molecular features of 
cytokine-differentiated CD34-lineage- cells. The expression of mRNA specific for the NK-associated transcription factor Id2 
and for Bcl-2 and GATA-3 was investigated by quantitative PCR (qPCR) in freshly isolated (day 0) and cytokine-differentiated 
CD34-lineage- cells (week +4), as previously detailed [5]. CD34+ cells from the same UCB samples were used as control. 
Panel B: TCRγ rearrangement status after in vitro exposure to IL-15 plus IL-21. The analysis of TCRγ rearrangement status 
was performed as detailed in Materials and Methods. Peripheral blood CD3+ T cells from healthy donors were used as control 
for TCRγ rearrangement status. CD34-lineage- cells cultured with IL-15 and IL-21 harboured un-rearranged TCRγ genes, simi-
lar to freshly isolated CD34-lineage- cells (day 0) and to cells maintained with SCF and Flt3-L either alone or supplemented with 
IL-21. M = marker. JP = rearrangement involving the Jγ and Cγ segments. The forward primer mapped to the JγP cassette, 
whereas the reverse primer mapped to the constant (C) region. JP1 = rearrangement involving the JγP1 region and the Cγ seg-
ment. The forward primer mapped to the JγP1 cassette, whereas the reverse primer mapped to the constant (C) region. JP2 = 
rearrangement involving the JγP2 region and the Cγ segment. The forward primer mapped to the JγP2 cassette, whereas the 
reverse primer mapped to the constant (C) region. J1/2 = rearrangement involving the Jγ1/2 region and the Cγ segment. The 
forward primer mapped to the Jγ1–2 cassette, whereas the reverse primer mapped to the constant (C) region. L = linker 
region (no rearrangement). Forward and reverse primers mapped to the spacer region between Vγ9 and Vγ10 segments.
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lineage- cells acquired the ability to release soluble factors
relevant for NK effector function and NK migration/hom-
ing.
Response of IL-21-differentiated NK cells to maturation 
stimuli
We asked whether a cytokine stimulus such as IL-12 could
further mature the population of NK cells differentiated
with IL-15 and IL-21. We recovered NK cells from 4 week-
old cultures of CD34-lineage- cells and CD34+ cells, and
we exposed them to exogenous IL-12 for additional 48
hours [25]. Cells were collected and used to assess the
expression of a restricted panel of NK-cell antigens,
whereas supernatants were used to measure TNF-α, MIP-
1α and GM-CSF release. As summarised in Figure 6A, no
appreciable modification of the expression levels of
CD16, CD56 and KIRs occurred after the exposure of IL-
15- or IL-15+IL-21-matured NK cells to IL-12. In line with
this observation, the release of MIP-1α, TNF-α and GM-
CSF was superimposable, irrespective of the provision of
IL-12 to cytokine-differentiated NK cells. Whereas IL-12
induced only a modest increase of CD56 expression on
CD34-derived NK cells, it significantly enhanced their
ability to secrete TNF-α and GM-CSF (Figure 6B). Because
equal numbers of cytokine differentiated NK cells were
used to detect IL-12-induced maturation, these experi-
ments also indicated that TNF-α and GM-CSF release on a
per cell basis was remarkably higher in CD34-lineage--
derived NK cells compared with CD34+-derived NK cells.
Functional assays of NK activity
CD34-lineage- cells cultured with IL-15 and IL-21 for 4
weeks were assayed for NK activity against NK-sensitive
Cytokine and chemokine release from CD34-lineage- cells and CD34+ cells differentiated with IL-15 and IL-21Figure 5
Cytokine and chemokine release from CD34-lineage- cells and CD34+ cells differentiated with IL-15 and IL-21. 
The production of GM-CSF, TNF-α and CCL3/MIP-1α in supernatants of CD34-lineage- cells and CD34+ cells maintained with 
SCF+Flt3-L either alone or supplemented with IL-15, IL-21 or the combination of both cytokines was monitored weekly with 
conventional ELISA. Bars depict mean and standard deviation recorded in 3 independent experiments performed in triplicate. 
FL = Flt3-L; W = week.
CD34-lineage- cells
CD34+ cells
P<0.01
P<0.001 P<0.01
P<0.01
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cells were first activated with IL-2 and then co-cultured at
escalating effector-to-target ratios with either NK-resistant
Raji cells or NK-sensitive K562 cells for 4 hours. The
expression of CD107a, a lysosomal protein whose up-reg-
ulation reflects exocytosis of secretory granules, on CD56+
NK cells was monitored by flow cytometry [26]. Control
cultures were established with NK cells differentiated
from UCB CD34+ cells under the same culture conditions
as those applied to CD34-lineage- cells. As shown in Figure
7, minor degranulation occurred when NK-resistant Raji
tumour cells were plated in co-culture with NK cells
derived from either CD34-lineage- cells or CD34+ HSC
(data not shown). Conversely, an average 65 ± 11% of
CD56+ NK cells stained positively for CD107a in co-cul-
tures established with NK-sensitive K562 cells and NK
cells differentiated from CD34-lineage- cells with IL-15
plus IL-21. Notably, NK cell degranulation occurred at sig-
nificantly lower levels in co-cultures containing K562 cells
and IL-15-differentiated CD34-lineage- cells (mean per-
centage of CD107a+CD56+ NK cells equal to 35 ± 6 at E:T
ratio = 1; p < 0.01), suggesting that IL-15 and IL-21 exerted
synergistic effects on NK activity. Finally, NK cells differ-
entiated from CD34+ HSC with either IL-15 alone or IL-
15+IL-21 manifested a similar cytotoxic activity to that of
IL-12-induced maturation of cytokine-differentiated NK cellsFigure 6
IL-12-induced maturation of cytokine-differentiated NK cells. CD34-lineage- cells (panel A) and CD34+ cells (panel B) 
were differentiated with SCF+Flt3-L supplemented with either IL-15 or IL-15+IL-21 for 4 weeks, as already detailed. After fur-
ther 48 hours of culture with 2 ng/ml IL-12, cells were harvested and used for flow cytometry experiments and for measure-
ments of cytokine/chemokine release. A representative flow cytometry profile out of 4 with similar results is shown. Markers 
were set according to the proper isotypic control. The blue bars depict cytokine/chemokine release in cultures that were not 
treated with exogenous IL-12, whereas red bars indicate cytokine/chemokine production in cultures exposed to IL-12. *P < 
0.01 compared with cultures established in the absence of IL-12.
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shown).
Discussion
NK cells are important effectors of the innate immune sys-
tem and exhibit cytolytic activity against infectious agents
and tumour cells. Although our knowledge of NK-cell
developmental intermediates remains limited, advances
have recently led to a better definition of appropriate cul-
ture conditions for the in vitro generation of mouse and
human NK cells from foetal thymus [27], foetal liver [28],
UCB [15] and bone marrow HSC [29]. In early studies,
NK-cell development from purified HSC was shown to be
stromal-cell dependent [30]. It has later been demon-
strated that the stromal-cell requirements may be replaced
by the provision of early-acting cytokines such as SCF,
Flt3-L and IL-7 to the cultures [31]. In particular, SCF and
Flt3-L directly induce the expression of IL-2 receptor-β
chain on HSC, thereby rendering them susceptible to the
NK-cell commitment induced by IL-15 [31]. Prolonged
culture of CD34+ HSC with IL-15 in the absence of stro-
mal cells can generate pseudo-mature lytic NK cells, e.g.,
cells expressing markers of mature NK cells (NK1.1 and
DX5 in mice, CD56 in humans, CD94-NKG2 receptors in
both species) but not Ly49 receptors or KIR [29,32]. More
recently, UCB CD34+ cells have been differentiated along
Degranulation assay with cytokine-differentiated NK cellsFigure 7
Degranulation assay with cytokine-differentiated NK cells. NK cell function was evaluated through flow cytometry 
monitoring of CD107a expression, following a previously described protocol [26]. CD34-lineage- cells initially differentiated 
with either IL-15 alone or the combination of IL-15 and IL-21 for 4 weeks were further activated for 24 hours with 100 IU/ml 
IL-2 (R&D Systems), followed by co-culture with NK-sensitive cells (K562) or NK-resistant cells (Raji). The different effector 
(E)-to-target (T) ratios indicated in the Figure were selected based on previous publications [26]. After 4 hours, cells were har-
vested, labeled with anti-CD107a and anti-CD56 mAb and analyzed by flow cytometry. The data shown here are representa-
tive of 4 independent experiments with similar results. The percentage of CD107a+CD56+ cells is indicated.
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sone but in the absence of any stromal cell support [16].
In addition, IL-21 may synergize with IL-7, IL-15, SCF,
Flt3-L and serum supplementation in promoting the gen-
eration of NK cells from UCB CD34+ cells [15].
The antitumor activity of IL-21 has been demonstrated in
murine experimental models where direct effects of IL-21
on NK cells were responsible for tumour suppression [33].
In addition, the ability of IL-21 to promote long-lasting
CD8+ T-cell-dependent tumour responses has been shown
in athymic mice with intraperitoneal or subcutaneous
tumours [34,35]. IL-21 may also augment human T-cell
proliferation driven by polyclonal activation or by a pep-
tide in the absence of other stimuli and may increase
CD8+ T-cell production of IFN-γ induced by IL-15 [36].
The aforementioned in vitro and pre-clinical findings have
prompted the evaluation of IL-21 as immunotherapy for
patients with metastatic melanoma and renal cell carci-
noma [37,38]. These studies have clearly shown that
repeated cycles of IL-21 are well tolerated as an outpatient
regimen, thus encouraging further development of IL-21
as an immunotherapy for cancer.
Early studies of UCB transplantation for haematological
malignancies have demonstrated an impaired rate and
quality of immune reconstitution, which may be associ-
ated with an increased rate of infectious complications,
particularly at early time points after transplantation [39].
These clinical observations reinforce the need for novel
cell-based therapeutic approaches to overcome the poten-
tially life-threatening infections, including those attribut-
able to a delayed anti-CMV immunity [40].
We provide evidence that IL-21 favours the NK cell differ-
entiation of CD34-lineage- UCB cells in cooperation with
IL-15 and in the absence of stromal cell support and
serum or hydrocortisone supplementation. The combina-
tion of IL-15 and IL-21 displayed a remarkable ability to
promote the outgrowth of CD34-lineage- cells into NK
cells, at variance with IL-21 alone. This is backed by previ-
ous observations indicating that the γc-dependent
cytokines IL-15 and IL-21 may integrate their signalling
and synergise in regulating CD8+ T-cell expansion and
function [13]. Using murine mature NK cells, Kasaian et
al. [41] have shown that IL-21 may constrain the IL-15-
induced expansion of NK cells in vitro, although their acti-
vation status remains unaffected, underpinning the con-
cept that IL-21 may exert diverging effects on murine as
opposed to human NK cells. It has also been demon-
strated that low doses of IL-21 increase the proliferative
response of murine NK cells to either IL-2 or IL-15,
whereas high doses of IL-21 may exert an inhibitory effect
on NK cell outgrowth [42]. In our study, IL-21 signifi-
cantly inhibited the proliferation of CD34+ cells induced
by SCF and Flt3-L, suggesting that IL-21 may also exert
opposite effects on HSC proliferation depending on the
concomitant cytokine stimulus that is applied.
It should be emphasised that CD34+ HSC differentiated
under the same cytokine conditions expanded more vig-
orously than their CD34-lineage- counterpart. Not unex-
pectedly, IL-21 promoted the activation of Stat1 and
Stat3, but not Stat5 protein, in CD34-lineage- cells. NK
cells generated in vitro with IL-15 and IL-21 acquired a
CD56+CD16-/+ phenotype which differs from the pheno-
type that we previously observed using Flt3-L, SCF, IL-15
and a stromal feeder layer, where NK progenitor cells
stained negatively for CD16 [5]. The percentage of CD56-
expressing CD34-lineage- cells was significantly higher
compared to that in cultures of CD34+ HSC, indicating
that the former HSC subset has the ability to give origin to
a virtually pure NK cell population when confronted with
IL-15 and IL-21 in vitro. The natural cytotoxicity receptor
NKp46 and the NKG2D antigen were strongly up-regu-
lated on CD34-lineage- cells cultured with the combina-
tion of IL-15 and IL-21. The activating receptor NKG2D,
whose ligands are frequently over-expressed in tumours
from multiple origins [43], could be detected at very low
levels in cultures performed with IL-15 alone. Conversely,
NKG2D expression levels significantly increased as a
result of combined treatment with IL-15 and IL-21, sug-
gesting that the NK cell populations obtained under these
culture conditions may represent suitable effectors for
cell-based anti-tumour therapeutic approaches. From a
molecular standpoint, IL-15 and IL-21 induced mRNA
signals for Bcl-2, GATA-3 and for the NK cell-associated
transcription factor Id2. Interestingly, NK cell differentia-
tion occurred through a pathway that does not involve
TCR rearrangement, indicating that the NK intermediates
originating from UCB CD34-lineage- cells differ from pre-
viously described bi-potent NK/T cells [27,28].
Considerable release of IFN-γ only occurred in 4-week old
cultures of CD34-lineage- cells maintained with IL-15 and
IL-21. Conversely, GM-CSF and TNF-α could be detected
in supernatants of cultures maintained with either IL-15
alone or IL-15 plus IL-21. Significant secretion of TNF-α
could be measured preferentially in cultures stimulated
with IL-15 alone. These findings are in good agreement
with previous reports on IL-21-induced changes of
cytokine secretion by UCB-derived CD34+ HSC [16]. In
the latter study, IL-21 increased IL-10 and GM-CSF pro-
duction but lessened TNF-α release after 4-week culturing
in the presence of hydrocortisone, Flt3-L and IL-15. CCL3/
MIP-1α production occurred under any culture condition
herein examined, although the highest production could
be documented after challenge with IL-15 and IL-21. ThePage 11 of 15
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21 in combination suggests that cytokine-differentiated
NK cells may retain the ability to mount effective anti-
viral and anti-tumour responses. The significant secretion
of CCL3/MIP-1α, a chemokine implicated in the selective
mobilization of NK cells from the bone marrow compart-
ment into the peripheral blood [44], implies that
cytokine-matured NK cells may provide in vivo signals
contributing to the regulation of NK homing, retention
and migration.
The NK cell populations differentiated with IL-15 and IL-
21 were resistant to further maturation with IL-12, as eval-
uated both in terms of surface membrane phenotype and
in terms of cytokine/chemokine release. Specifically, the
expression levels of CD16, CD56 and KIR were similar
irrespective of the provision of exogenous IL-12. Simi-
larly, CCL3/MIP-1α, TNF-α and GM-CSF release were
superimposable in cultures of IL-15+IL-21-differentiated
cells that were either stimulated with IL-12 or left
untouched.
Finally, the NK cells differentiated with IL-15 and IL-21
underwent exocytosis of secretory granules, as measured
by a flow cytometry-based CD107a degranulation assay,
upon co-culturing for 4 hours with NK-sensitive tumour
cell targets, indicating the acquisition of cytolytic poten-
tial. However, the extent of NK granule exocytosis was
comparable to that measured in co-cultures of K562 cells
and NK cells differentiated from CD34+ HSC with the
combination of IL-15 and IL-21.
Conclusion
This study suggests that considerable numbers of highly
pure, lytic CD56+CD16-/+ NK cells for adoptive immuno-
therapy can be obtained from UCB CD34-lineage- cells
using a serum-free, feeder cell-free culture system. From a
qualitative standpoint, these NK populations differ from
those differentiated from UCB CD34+ HSC insofar they
express high levels of the activating receptor NKG2D,
release high quantities of IFN-γ, GM-CSF and TNF-α and
are resistant to maturation with IL-12. The findings high-
lighted herein also shed some light into the developmen-
tal intermediates of NK cells that can be differentiated
after the exposure of CD34-lineage- cells to IL-21.
Methods
Isolation and culture of human CD34-lineage- cells
CD34-lineage- cells were purified from UCB samples col-
lected after full-term delivery from consented donors [5].
All investigations were approved by local Human
Research Committees. Briefly, UCB mononuclear cells
were obtained by Ficoll-Hypaque density gradient centrif-
ugation and CD34+ cells were separated using the MACS
system (Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many). The CD34- fraction was further depleted of line-
age+ cells, as previously detailed [5]. Freshly isolated
CD34-lineage- cells comprised 0.22 ± 0.09% of UCB
mononuclear cells (number of samples analyzed = 8) and
stained negatively for lymphoid/NK cell markers (not
shown and previously published data [5]). CD34-lineage-
cells were cultured with MyeloCult™ H5100 (Stem Cell
Technologies, Vancouver, Canada) supplemented with
10-6M hydrocortisone (Sigma Aldrich, Milan, Italy), 20
ng/ml SCF and 20 ng/ml Flt3-L (R&D Systems, Oxon,
Cambridge, United Kingdom). IL-15 (50 ng/ml) and/or
IL-21 (20 ng/ml; R&D Systems) were added to SCF/Flt3-L-
containing cultures as specified in the Figure legends. In
selected experiments, 2 ng/ml IL-12 was provided to the
NK-cell cultures for 2 days in the attempt to induce com-
plete phenotypic and functional maturation [45].
Flow cytometry
Cells were incubated for 30 minutes at 4°C with fluoro-
chrome-conjugated monoclonal antibodies (mAb) to
CD16, CD34, CD56 (BD Biosciences, Mountain View,
CA), CD94, CD158a, CD158b (Pharmingen, San Diego,
CA), NKG2A, IL-21 receptor (R&D Systems), CD45
(Caltag Laboratories, Burlingame, CA), CD94, NKp46
(CD335), NKG2D (CD314; Beckman Coulter, Milan,
Italy). Isotype-matched, fluorochrome-conjugated mAb
from the same manufacturers were used to control for
background fluorescence. Cells were run through a FACS
Canto® flow cytometer (BD) with standard equipment
[46].
CD107a degranulation assay
NK cells were activated with 100 IU/ml IL-2 for 48 hours.
After washings with PBS, NK cells were co-cultured for 4
hours with either K562 (NK-sensitive) or Raji cells (NK-
resistant) at 1:1, 1:3 and 1:10 effector-to-target (E:T) ratio,
as previously published [26]. Thereafter, cells were
labelled with PE-conjugated anti-CD56 and FITC-conju-
gated anti-CD107a antibodies (both from BD Bio-
sciences) for 20 minutes at 4°C, followed by flow
cytometry analysis. Isotype-matched antibodies from the
same manufacturer were used to assess background fluo-
rescence.
Reverse transcriptase polymerase chain reaction (RT-PCR)
Details on RNA extraction were previously published
[47,48]. One μg of total RNA was reverse-transcribed with
25 U of Moloney murine leukaemia virus reverse tran-
scriptase (PE Applied Biosystem, Foster City, CA) at 42°C
for 30 minutes in the presence of random hexamers. Two
μl of cDNA products were amplified with 1 U of AmpliTaq
Gold (PE Applied Biosystem) in the presence of primers
specific for the RNA of interest [49]. Amplification of
human Id2 mRNA (GI 464183) was achieved by 29 cycles
of 45 seconds at 56°C and 1 minute at 72°C, using thePage 12 of 15
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CAGCATCCTGTCCTT-3' and 5'-CATTCAGTAGGCTTGT-
GTGA-3'.
Analysis of TCRγ rearrangement
The extraction of genomic DNA was performed with the
QIAamp DNA Blood Mini Kit (Qiagen, Milan, Italy). The
analysis of TCRγ rearrangement was conducted with prim-
ers listed in Table 2 (GI 28436398). The reaction mixtures
contained 10× PCR buffer, 0,8 μM of each dNTP, 3 mM
MgCl2, 0.2 mM of each primer, 5% DMSO and 1,25 U of
Amplitaq Gold (PE Applied Biosystem). Four separate
reaction mixes were prepared with each one containing a
Jγ direct primer coupled with a reverse primer specific for
the constant region. Control PCR were run with two reac-
tion mixes, one containing a direct and reverse primer
mapping in the constant region segment and the other
containing a direct and reverse primer mapping in the
TCR linker region (Table 2). Semi-nested PCR were per-
formed using internal reverse primers.
Measurement of cytokine and chemokine release
The production of IFN-γ, GM-CSF, TNF-α and MIP-1α by
CD34-lineage- cells and CD34+ cells differentiated with IL-
15 and IL-21, either alone or in combination, was investi-
gated after their activation with 10 μg/ml PHA for 18
hours. Culture supernatants were harvested and IFN-γ,
GM-CSF, TNF-α and MIP-1α were quantitated using com-
mercially available ELISA (R&D Systems, Oxon, Cam-
bridge, UK). The minimum detectable doses, as reported
by the manufacturer, were as follows: 8 pg/ml IFN-γ; < 3
pg/ml GM-CSF; 1.6 pg/ml TNF-α; < 10 pg/ml CCL3/MIP-
1α.
Detection of Stat1, Stat3 and Stat5 activation
The relative amount of Stat1 (Tyr701), Stat3 (Tyr705) and
Stat5 (Tyr694) phosphorylation after IL-21 provision to
CD34-lineage- cells was determined with phospho-Stat-
specific mAb, following the manufacturer's instructions
(RayBio® Cell-Based STAT ELISA Sampler Kit; RayBiotech
Inc., Norcross, GA). Briefly, 20–30 × 103 CD34-lineage-
cells were seeded in a 96-well plate and incubated over-
night at 37°C, 5% CO2. IL-21 was then added to the wells
at 20 ng/ml (final concentration) for up to 4 hours, as
detailed in the Figure legends. After cytokine challenge,
cells were fixed and extensively washed with the appropri-
ate buffer solution, and then incubated with antibodies
directed against phosphorylated Stat proteins for 2 hours
at room temperature. After further washings, cells were
incubated with HRP-conjugated anti-mouse IgG for 1
hour and treated with 3,3',5,5'-tetramethylbenzidine
(TMB) substrate solution for 30 minutes at room temper-
ature. Optical density (OD) was immediately measured at
450 nm.
Quantitative PCR
A real-time quantitative RT-PCR for the genes of interest
(GATA-3, IDH2, BCL-2, CD34, GAPDH; Table 3) was per-
formed with the iCycler iQ system (Bio-Rad, Hercules,
Table 2: Primers used to detect TCRγ rearrangement in cytokine-differentiated CD34-lineage- cells.
Primer Sequence (5'-3') Region Orientation
TCRL TCCTACTGATCACTGTGCTG Linker (L) region F
TCRL-IR GGCCTTAAGTTGGCTGCATC R
TCRL-ER TGTTCTGTTGGAGATGGGAC R
TCR 1/2 CGCATATCATCTGTCAGAAC Constant (C) region F
TCR 1/2IR TACCACGTGTCACGTTGCTA R
TCR 1/2ER TGTCAACAATGAACCCGTTG R
JγPF AATCAAGGTATTTGGTCCCG J cassette F
JγP1F TACCACTGGTTGGTTCAAGA F
JγP1/2F AAAGGGACTAGGCTCATAGT F
Jγ1/2F AACAACACTTGTTGTCACAG F
Abbreviations: TCRL = TCR linker; TCRL-I = TCR linker internal; TCRL-E = TCR linker external; ER = external reverse; IR = internal reverse; F = 
forward; R = reverse.
Table 3: Primers used to detect gene expression by qPCR in 
cytokine-differentiated CD34-lineage- cells.
Primer Sequence (5'-3') Orientation
IDH2 ACTACATCAGGGACCTTCAG F
IDH2 TATAAGGATGATCTAGTGGTCG R
BCL-2 AGGAAACTTGACAGAGGATCATGC F
BCL-2 CGGATCTTTATTTCATGAGGCACG R
GATA-3 AGGAGGAATGCCAATGGGGAC F
GATA-3 TCGGTTTCTGGTCTGGATGCC R
CD34 TCTTGACAACAACGGTACTGCTAC F
CD34 GCTGGTACTTCCAAGGGTACTAGG R
GAPDH CCTGACCTGCCGTCTAGAAA F
GAPDH CTCAGTGTAGCCCAGGATGC RPage 13 of 15
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cytokine-conditioned cells. Complementary DNA
(cDNA) was prepared starting from 1 μg of total RNA,
after DNase I treatment (Amersham Pharmacia biotech,
Buckinghamshire, UK) using the iScrypt cDNA Synthesis
Kit (containing RNase H + MMLV reverse transcriptase
random primers and 5× reaction mixture (Bio-Rad)
according to the manufacturer's instructions. Reactions
were conducted in the PTC-0200 DNA Engine (MJ
RESEARCH). Amplification was carried out in a total vol-
ume of 25 μl containing 0.3 μM of each specific primer,
12,5 μl 2× SYBR Green Master Mix (Bio-Rad) (containing
100 mM KCl, 40 mM Tris-HCl, pH8.4, 0.4 mM of each
dNTP, iTaq DNA Polymerase, 6 mM MgCl2, SYBR Green I,
20 nM fluorescein, stabilizers) and 2 μl of diluted cDNA.
The PCR reactions were cycled starting with a 3-minute
template denaturation step at 95°C followed by 40 cycles
of 15 seconds at 95°C and 1 minute at 60°C. Comple-
mentary DNA from heart tissue cells was used as control
in each set of reactions. Standard curves were generated
using a serial dilution of the initial amount of control
cDNA to determine the range of template concentration,
which showed a good linearity (0,998–0,999) and effi-
ciency (>90%) for the different reactions. Melt curves of
the reaction products were also generated to assess the
specificity of the measured fluorescence. Samples were
run in triplicate and the mean of threshold cycles (Ct) for
each specimen was used to obtain the fold change of
GATA-3, IDH2, BCL-2, and CD34 expression level, using
the following equation:
where ΔCt = Ct specific gene -Ct GAPDH and Δ(ΔCt) = ΔCt specimen
- ΔCt control. A sample with a 1-fold change represents a
sample with the same expression level as the reference
control for a target gene. Calculations were performed
with the Excel spreadsheet RelQuant (Bio-Rad, last update
January 2004). Primer sets were designed using the Bea-
con Design Software (Version 3) and the sequences avail-
able in the GeneBank™ data base. The specific
oligonucleotide primer sequences are detailed in Table 3.
Statistical methods
The approximation of population distribution to normal-
ity was tested preliminarily using statistics for kurtosis and
symmetry. Data were presented as mean ± SD and com-
parisons were performed with the Student's t test for
paired or unpaired data or with the analysis of variance, as
appropriate. The criterion for statistical significance was
defined as p = .05.
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